Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FMDW2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $68,330
Award facts
- Contract value 100% obligated
- $68,329.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $68,329.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The award, issued on November 12, 2025, with an ultimate completion date of November 13, 2025, utilized no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V initiative, a $499.999 billion contract vehicle awarded on November 13, 2025, designed to support recurring pharmaceutical supply needs for Department of Defense military healthcare facilities worldwide through 2036.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's extensive product portfolio spans branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to fulfill diverse and specialized pharmaceutical requirements across the broader $30.3 billion PPV-G GEN V acquisition strategy. The Entyvio delivery order represents one of numerous awards issued to the contractor, reflecting consistent performance in delivering specialized pharmaceutical products to support Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FMDW2?
SPE2DR26FMDW2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DR26FMDW2 worth?
The government has obligated $68,330 on SPE2DR26FMDW2.
Is contract SPE2DR26FMDW2 an order under another contract?
Yes. SPE2DR26FMDW2 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDW2 competed?
The extent of competition for SPE2DR26FMDW2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award